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ABSTRACT
Nucleic acids that bind to cells and are sub-
sequently internalized could prove to be novel deliv-
ery reagents. An anti-prostate specific membrane
antigen aptamer that has previously been shown to
bind to prostate tumor cells was coupled to siRNAs
via a modular streptavidin bridge. The resulting
conjugates could be simply added onto cells with-
out any further preparation, and were taken up
within 30 min. The siRNA-mediated inhibition of
gene expression was as efficient as observed with
conventional lipid-based reagents, and was depend-
ent upon conjugation to the aptamer. These results
suggest new venues for the therapeutic delivery of
siRNAs and for the development of reagents that
can be used to probe cellular physiology.
INTRODUCTION
One of the key problems facing the development of siRNA
and other small molecule therapeutics is delivery, both sys-
temic and to speciﬁc cell or tissue types (1,2). A variety of
small molecules, lipids, peptides and proteins have previously
been examined as potential delivery vehicles and vectors
for nucleic acids. For example, the non-speciﬁc uptake of
cholesterol labeled siRNAs has been demonstrated to be
effective for delivery to cells grown in culture as well to
liver, heart, kidney and lung tissue in mice (3). Similarly,
a portion of the HIV-1 gp41 protein fused to a nuclear
localization sequence has been demonstrated to be an
effective means for the general delivery of siRNAs in tissue
culture (4,5).
Peptides have also been utilized for the cell-speciﬁc deliv-
ery of siRNAs. For example, Shchiffelers et al. utilized
PEGylated polyethyleneimine and an integrin-binding RGD
peptide to direct siRNA uptake to tumor neovalsulature (6).
In addition to small peptides, larger, protein-based targeting
moieties have also been utilized. For example, the iron-
binding protein transferrin has been used to target colloids
composed of siRNA and cyclodextrin-containg polycations
to transferrin receptor-expressing tumor cells (7). More
recently, the tissue-speciﬁc delivery of siRNAs has been
achieved using fusions between protamine and antibodies.
In this system, siRNAs were bound by the basic protamine
and then targeted to tumor cells via antibodies. In one
example, by using a fusion to an anti-ERbB2-speciﬁc single
chain antibody, siRNAs could be targeted to tumor cells
expressing the epidermal growth factor receptor ERbB2 (8).
Selected nucleic acid binding species (aptamers) are
frequently viewed as non-protein based alternatives to anti-
bodies and are thus also potential targeting agents for the
delivery of siRNA cargoes (9). In addition to possessing
high afﬁnity and speciﬁcity for their targets, aptamers can
be synthesized chemically and thus are attractive reagents
for use in therapeutic and other applications where quality
control is critical. Aptamers targeting surface antigens as
well as whole cells have previously been selected (10–13).
More importantly, it has recently been reported that nucleic
acids selected to bind to a cell surface marker, prostate-
speciﬁc membrane antigen, can themselves be internalized.
These anti-PSMA aptamers have been shown to be capable
of carrying a nanoparticle into cells expressing this antigen
(14). Building on these ﬁndings, we wished to determine
whether anti-PSMA aptamers could also deliver functional
siRNA molecules to a cell. To do this we have generated
an aptamer:streptavidin:siRNA conjugate. Delivery using
these aptamer conjugates was found to be efﬁcient and spe-
ciﬁc for cells expressing the PSMA antigen.
MATERIALS AND METHODS
Aptamer synthesis
The anti-PSMA aptamer (A9) was synthesized by runoff
transcription from a double-stranded DNA template bearing
a T7 RNA polymerase promoter. All transcription reactions
(20 ml) were performed in 40 mM Tris (pH 8.0) 30 mM
MgCl2 and 5 mM spermidine, and contained 2 mg aptamer
template, 1 mM ATP and GTP, 2 mM2 0F dCTP and 20F dUTP
(TriLink Biotech, CA) and 0.5 ml of the mutant T7 RNA
polymerase Y639F (15). Reactions were carried out for
8ha t3 7  C prior to DNase treatment for 10 min at 37 C.
The modiﬁed RNA products were puriﬁed by denaturing
(7 M urea) gel electrophoresis on an 8% polyacrylamide
gel. After excision from the gel the RNA was eluted over-
night in water and recovered by ethanol precipitation.
Aptamer biotinylation
Puriﬁed aptamer (150 nM) was oxidized in 100 mM NaOAc
(pH 5.0) and 100 mM NaIO4 for 90 min at room temperature
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equal volume of 50% glycerol (1 ml) and the RNA was pre-
cipitated with ethanol. The oxidized RNA was then reacted
with 200 pmol of freshly prepared biotin-hydrazide (Pierce,
Rockford, IL) in 500 mL of 100 mM NaOAc (pH 5.0). The
reaction was allowed to proceed for 3 h at room temperature
and the free biotin hydrazide was removed using a NAP
5 column (Amersham Biosciences, Pittsburg, PA). The
modiﬁed RNA was gel-puriﬁed, and the extent of biotinyla-
tion was conﬁrmed by gel-shift analysis on a denaturing
(7 M urea, 8% polyacrylamide) gel (16). Typical yields of
biotinylated RNA were  50–60%.
siRNA synthesis
The sequence of the anti-Lamin A/C siRNA used was
50-GGAACUGGACUUCCAGAAGAACAUCUA (sense) and
50-UAGAUGUUCUUCUGGAAGUCCAGUUCC (antisense).
The sequence of the anti-GAPDH siRNAs used were
GAPDH1, 50-GGCGCUGCCAAGGCUGUGGGCAAGGUC
(sense) and 50-GACCUUGCCCACAGCCUUGGCAGCGUC
(antisense); and GAPDH2, 50-GGCAUUGCCCUCAACGAC-
CACUUUGUC (sense) and 50-GACAAAGUGGUCGUUGA-
GGGCAAUGUC (antisense).
All non-biotinylated antisense strands and the biotinytlated
GAPDH sense strands were purchased from IDT (Corriville,
IA). The 50-biotinylated sense 27mer RNA (B-RNA) and
50-biotinylated sense 27mer RNA with a disulﬁde linker
(BSS-RNA) were synthesized on an Expedite 8909 DNA
synthesizer (Applied Biosystems, Foster City, CA) using
TOM phosphoramidites. All synthesis reagents were pur-
chased from Glen Research (Sterling, VA). The 50-biotin
was added to the RNA using a 50-biotin phosphoramidite.
The 50-biotin with a disulﬁde linker was synthesized via the
addition of a C6 S-S thiol modiﬁcation during synthesis
followed by the addition of the 50-biotin phosphoramidite.
RNA oligonucleotides were deprotected for 24 h in
3:1 NH4OH:ethanol at room temperature. Following lyophil-
ization, the RNA was deprotected in NMP/TEA/THF for
1.5 h at 65 C and recovered by butanol precipitation. The
bioinylated RNA was puriﬁed by reverse phase HPLC on
an Xterra C18 MS 2 mm column at 60 Ci n1 0 0m M
TEAA (pH 7) with a gradient of 5–35% acetonitrile over
30 min. After lyophilization the biotinylated RNA was further
puriﬁed on a denaturing (7 M urea, 10% polyacrylamide) gel.
RNA was eluted from the gel in water and recovered by
ethanol precipitation.
Aptamer and siRNA conjugation to streptavidin
Sense and antisense strands of siRNA (40 mM) were annealed
in 100 mM KOAc, 30 mM HEPES–KOH (pH 7.4) and 2 mM
MgOAc. Samples were heated to 94 C for 30 s and then
cooled stepwise in 30 s increments to 72, 52 32, 22, 12 and
4 C. Aptamer:siRNA complexes were assembled by mixing
200 pmol double-stranded siRNA and 200 pmol biotin-
aptamer conjugate with 100 pmol of streptavidin (Promega,
Madison, WI). The complex was allowed to equilibrate
for a minimum of 10 min and was then stored on ice until
used. Aptamer:streptavidin:siRNA conjugates were added
directly to media at ﬁnal concentration of 22.5 nM.
Transfections
LNCAP cells (ATCC CRL-1740) and PC3 cells (ATCC
CRL-1435) were purchased from ATCC. LNCaP cells were
incubated in RPMI 1640 (Gibco) media supplemented
with 2 mM L-glutamine, 1.5 g/L glucose, 10 mM HEPES,
1.0 mM sodium pyruvate, and 10% FBS. PC3 cells were
incubated in HAM’s F12K media (ATCC) media supple-
mented with 2 mM L-glutamine, 1.5 g/l sodium bicarbonate
and 10% FBS. For transfections and conjugate delivery,
cells were grown to 70% conﬂuence in 12 well plates.
For aptamer-mediated siRNA delivery, aptamer:streptavi-
din:siRNA conjugates were added directly to the media
(500 ml) at a ﬁnal concentration of 45 nM siRNA or
22.5 nM conjugate (average of 2 siRNAs/conjugate). Cells
were harvested 72 h after the addition of the conjugate and
monitored for gene expression inhibition by real-time PCR.
Alternatively, Oligofectamine (2 ml; Invitrogen, Carlsbad,
CA) was mixed with 100 ml of media and added to 100 ml
of media containing 22.5 pmol aptamer:streptavidin:siRNA
conjugate. After incubating for 10 min at room temperature,
the mixture was diluted to 1 ml with media (without FBS)
and 300 ml was added to cells. Transfections were incubated
for 4 h at 37 C after which the media was removed and
replaced with 400 ml of fresh media containing 10% FBS.
Cells were harvested 72 h after the addition of the conjugate
and monitored for gene expression inhibition by real-time
PCR.
Real-time PCR
Total cellular mRNA from each well was extracted with
Trizol (400 ml; Invitrogen, Carlsbad, CA). After incubation
for 5 min, the samples were diluted with 300 ml water and
extracted with phenol/chloroform/isoamylalcohol (700 ml).
The RNA was recovered from the aqueous phase by
ethanol precipitation. The pelleted RNA was resuspended in
20 ml of water.
Lamin A/C expression was analyzed by real-time PCR.
The mRNA for GAPDH served as an endogenous control.
For experiments in which both lamin A/C and GAPDH
were monitored (Figure 4), 18S rRNA served as the endo-
geneous control. The primers and probes used were as
follows: Lamin A/C forward primer, 50-ATGATCGCTTG-
GCGGTCTAC; lamin A/C reverse primer, 50-GCCCTGC-
GTTCTCCGTTT; lamin A/C probe 50-FAM-TCGACC-
GTGTGCGCTCGCTG-TAMRA; GAPDH forward primer,
50-GAAGGTGAAGGTCGGAGT; GAPDH reverse primer,
50-GAAGATGGTGATGGGATTTC; GAPDH probe,
50-Joe-CAAGCTTCCCGTTCTCAGCC-BHQ; 18S forward
primer, 50-TTGACTCAACACGGGAAACCT; 18S reverse
primer, 50-AGAAAGAGCTATCAATCTGTCAATCCT;
18S probe, 50-TET-ACCCGGCCCGGACACGGA-TAMRA;
INFB forward, 50-CCAACAAGTGTCTCCTCCAAATT;
INFB reverse, 50-GTAGGAATCCAAGCAAGTTGTAGCT;
INFB probe, 50-FAM-TGTTGTGCTTCTCCACTACAGC-
TCTTTCCA-BHQ.
Extracted RNA ( 200 ng) was reverse-transcribed in a
10 ml reaction containing 1 ml1 0 · ﬁrst strand synthesis buffer
(Ambion, Austin, TX), 0.2 mM dNTPs, 0.4 ml RNasin Plus
(Promega, Madison WI), 0.4 ml MMLV RT (Ambion, Austin,
TX) and 1 mM reverse primers. Reactions were carried out at
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(25 ml) contained 10 mM Tris (pH 8.3) 50 mM KCl, 1.5 mM
MgCl2, 0.25 U Taq (NEB, Cambridge, MA), 450 nM forward
and reverse primers and 125 nM probe, and 1 ml of the
reverse transcription reaction.
All reactions were conducted on either an ABI 7900 or
ABI 7300 real-time PCR machine (Applied Biosystems,
Foster City, CA) using the following cycling parameters,
95 C for 2 min, followed by 45 cycles of 95 C for 15 s,
60 C for 1 min. The amounts of lamin A/C mRNA in treated
and control cells were determined in comparison with the
endogeneous GAPDH control mRNA. All data represent
the average of three replicates except for those in Figure 5,
which are the average of two replicates. Error bars represent
±1 SD from the mean.
RESULTS
Design of aptamer:siRNA conjugates
The exogenous delivery of 21mer and more recently 27mer
RNA duplexes has been shown to be a highly effective
means of reducing gene expression in eukaryotic cells
(17,18). In addition, inhibition of expression has been medi-
ated by the delivery of short hairpin RNAs to cells (19).
Sequence extensions of siRNAs have previously been
found to compromise the processing and function of
these molecules. Therefore, it was possible that extending
siRNA sequences in order to couple them with aptamers
might have impeded siRNA function. In contrast, some
non-nucleotide modiﬁcations of siRNAs have been shown
to have little effect on function. For example, a ﬂuorescent
reporter appended to the 50 end of the sense strand of a
21mer siRNA had little or no effect on the ability of the
siRNA to inhibit gene expression (20,21). Similarly, ﬂuores-
cent modiﬁcations of a 27mer siRNA still allowed for
processing by Dicer and for inhibition of gene expression
in vivo (18).
Bearing this in mind, we chose to utilize 27mer siRNAs in
our design. In addition, we chose to couple the aptamers and
siRNAs using a modular strategy in which the RNAs were
ﬁrst biotinylated and then non-covalently joined to one
another via the protein streptavidin (Figure 1). Since it was
possible that the bulky streptavidin substituent might inhibit
siRNA processing in vivo, we designed two different bio-
tinylated sense strands, one containing a 50-biotin (Figure 1;
B-siRNA) and one containing a disulﬁde linkage to biotin
(Figure 1; BSS-siRNA). The disulﬁde linkage in the latter
construct should be cleaved upon entering the reducing envir-
onment of the cell, releasing the siRNA for processing or
fucntion. RNA conjugation to streptavidin and subsequent
cleavage of the BSS-siRNAs were conﬁrmed by gel-shift
analysis (Figure 2). Only the biotinylated siRNA constructs
were shifted in the presence of streptavidin, and only the
disulﬁde-containing BSS-siRNA was released from strep-
tavidin upon treatment with DTT.
Previous studies of nanoparticle delivery had relied upon
an anti-PSMA aptamer known as A10 (14). However, another
aptamer (A9) appeared to bind more tightly to PSMA (22),
and thus we chose to use it for the development of aptamer
delivery reagents. The anti-PSMA aptamer A9 delivery
reagent was synthesized by runoff transcription and was oxid-
ized at its 30 end using sodium periodate. The resultant dial-
dehyde was biotinylated by incubation with biotin-hydrazide.
A 27mer siRNA was designed based on the 21mer sequence
used by Elbashir et al. (17) and was used as a ‘cargo’ for the
internalizing, anti-PSMA aptamer. As a positive control, the
27mer was transfected into cells with Oligofectamine and
gene inhibition was analyzed by both real-time PCR and
western blot analysis (data not shown). Similarly, when the
B-siRNA or BSS-siRNA were transfected into cells, the
observed level of inhibition was similar to that seen with
the unmodiﬁed siRNA, conﬁrming that 50 modiﬁcation of
the sense strand did not signiﬁcantly affect siRNA function.
The siRNAs and biotinylated siRNAs (sense strands) were
synthesized using standard phosphoramidite chemistry. The
aptamer:streptavidin:siRNA conjugates were generated by
incubating the biotinylated anti-lamin A/C siRNA, biot-
inylated anti-PSMA aptamer and streptavidin in a 2:2:1
ratio for 10 min.
Cellular delivery of aptamer:siRNA conjugates
Aptamer:siRNA conjugates at a ﬁnal concentration of
22.5 nM (45 nM siRNA, average of 2 siRNAs/conjugate)
were added directly to media containing (PSMA-positive)
LNCaP cells. It should be noted that this procedure
Figure 1. Design of aptamer:siRNA conjugates. 27mer siRNAs (siRNA)
were synthesized as either biotin conjugates (B-siRNA), or with a cleavable
biotin linker (BSS-siRNA). Conjugates were assembled by incubation with
streptavidin and on average each conjugate should have contained two
siRNAs and two anti-PSMA aptamers.
Figure 2. Gel-shift analysis of siRNA:streptavidin conjugates. In the presence
of streptavidin, only the biotinylated siRNAs are shifted. The addition of
DTT results in the reduction of the disulfide bond in the BSS-siRNA
construct, releasing the 27mer duplex from streptavidin.
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delivery reagents: no additional components or preparations
were necessary to initiate experiments to assess the inhibition
of gene expression. After 72 h, treated cells were harvested,
the RNA was extracted with Triazol and the extent of gene
inhibition was determined by real-time PCR.
While all of the Oligofectamine transfected samples con-
taining either biotinylated or non-biotinylated siRNA resulted
in efﬁcient inhibition of expression (Figure 3a, blue), in the
absence of Oligofectamine, signiﬁcant inhibition of expres-
sion was only observed when both the biotinylated siRNA
and biotinylated anti-PSMA aptamer were present and joined
to one another (Figure 3a, yellow arrows). No inhibition of
expression was observed in the absence of an aptamer target-
ing domain, when the biotinylted aptamer was replaced with
a biotinylated random sequence RNA (Figure 3a; N30), or
when streptavidin was not included in the reaction mixture
(data not shown). Surprisingly, the presence of the bulky
streptavidin molecule seemed to have little or no effect on
the ability of the attached siRNAs to function; Oligofectam-
ine and aptamer-mediated transfections included identical
amounts of siRNA and gave comparable results. The speciﬁ-
city of the anti-PSMA aptamer was further conﬁrmed by car-
rying out a similar assay with the same anti-lamin A/C siRNA
conjugates and PSMA-negative PC3 cells. In these experi-
ments, only cells transfected via Oligofectamine showed
inhibition of gene expression (Figure 3b).
Similar results were observed with LNCaP cells when
two different siRNAs were used to target GAPDH mRNAs
instead of lamin A/C mRNAs (Figure 4; GAPDH1 and
GAPDH2). Importantly, the siRNAs directed against GAPDH
did not decrease the level of lamin A/C expression, while
siRNAs directed against lamin A/C did not decrease the
level of GAPDH expression. In addition, because siRNAs
can potentially activate the cellular immune response
(18,23,24)? cells were also monitored for the expression of
interferon b mRNA (INFB). As shown in Figure 4, exposure
to the aptamer conjugates for up to 72 h does not result in an
interferon response. As a positive control, cells were exposed
to LPS, which resulted in a three order of magnitude increase
in interferon mRNA expression (data not shown).
Aptamers mediate fast inhibition of gene expression
PSMA endoctyosis in LNCaP cells is thought to proceed pre-
dominantly via clathrin-coated pits. The rate of internaliza-
tion has previously been measured using antibodies directed
against PSMA and with another anti-PSMA aptamer (A10),
Figure 3. Aptamer-mediated inhibition of expression of lamin A/C. LNCaP cells (a) or PC3 cells (b) were incubated with streptavidin conjugates containing
(i) either no aptamer, a biotinylated anti-PSMA aptamer (PSMA) or a biotinylated random RNA pool (N30) and (ii) either a biotinylated siRNA (B-siRNA),
a cleavable biotinylated siRNA (BSS-siRNA) or a non-biotinylated siRNA (siRNA). All samples contained streptavidin. Inhibition of gene expression was
only observed for PSMA-positive LNCaP cells when the biotinylated PSMA aptamer and biotinylated siRNAs were connected to one another via streptavidin
(yellow arrows). Positive control transfections were carried with same conjugates and Oligofectamine (blue). Data represent the average of three replicates.
Error bars represent ±1 SD from the mean.
Figure 4. Aptamer-mediated siRNA delivery to LNCaP cells. Cells were
incubated with conjugates composed of streptavidin, the anti-PSMA aptamer
and either an anti-lamin A/C siRNA (LAC) or one of two anti-GAPDH
siRNAs (GAPDH1, GAPDH2) for 72 h prior to RNA extraction. Gene
expression for lamin A/C, GAPDH and interferon b (INFB) was assayed by
real-time PCR.
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anti-PSMA aptamer that we have used [a 20 nM Kd for
A10 versus 2 nM for A9 (22)]. For both types of targeting
agents, internalization was shown to take place within
hours of binding (14,25). These results suggested that efﬁci-
ent inhibition of gene expression might be quickly achieved
following only a brief exposure to aptamer:siRNA con-
jugates. To test this hypothesis, we performed a series of
reactions in which we varied the incubation time with apta-
mer:siRNA conjugates from 30 min to 72 h. After incubation
the media was removed and replaced with fresh media con-
taining no conjugate. All treated cells were then harvested
after 72 h and the extent of gene expression inhibition
was determined by real-time PCR. As shown in Figure 5,
inhibition was observed after only a 30 min exposure and
no increase in the level of inhibition was observed when
the exposure time was increased. This rate of internalization
is consistent with those previously observed. These results
also suggest a reason why aptamer:siRNA conjugates were
as effective as Oligofectamine amalgams. Even though the
aptamers and siRNAs were essentially ‘naked’ to serum
nucleases in the tissue culture media, they were taken up
into the cell so quickly that no real protection (such as
being ensconced in Oligofectamine) seemed to be necessary.
DISCUSSION
The development of nucleic acid reagents that can be used to
internalize biomolecular cargoes is not only novel, but also
extremely practical. Unlike lipid amalgams, nucleic acids
can target speciﬁc cell types. Unlike peptides, conjugation
chemistry between nucleic acid partners can potentially
involve either simple hybridization or co-synthesis. While
the simpliﬁcation of conjugation chemistry may not initially
seem to be a great advantage, quality control is one of the
most time- and labor-intensive portions of pharmaceutical
production, and any simpliﬁcation at this step should result
in great savings throughout the process.
We have used streptavdin as a non-covalent linker primar-
ily because of its ease of use and modularity. While strep-
tavidin conjugates and fusion proteins have previously been
used as imaging agents (26,27) and for the targeted delivery
of therapeutics in whole animals (28,29) as well as in clinical
trials (30), such conjugates have also been shown to elicit an
immune response (31). Therefore, immunogenicity may limit
the use of streptavidin as a delivery vehicle for siRNAs, at
least until less immunogenic streptavidin variants can be
identiﬁed (32). It may also be possible to conjugate aptamers
to siRNAs via linkers other than streptavidin, including by
simple co-synthesis or hybridization.
Nonetheless, there are some advantages to modular con-
jugation via a streptavidin bridge that we have developed
here. For example, the use of streptavidin may provide a con-
venient platform for further dissecting siRNA and microRNA
processing machinery in vivo. It seems likely that the siRNAs
must be removed from streptavidin prior to entry into
RNA-initiated silencing complexes. By varying the linker
length and chemistry between the biotin moiety and the
siRNA, it may be possible to probe the initial processing
steps for siRNAs separate from downstream assembly steps
and gene regulation.
Importantly, since streptavidin is a tetramer and has four
functional binding sites for biotin, internalizing and thera-
peutic nucleic acids can be mixed and matched. This will
be especially important for the future development of
siRNA therapeutics and reagents. By using the streptavidin
bridge and a judicious mixture of siRNAs, the uniform deliv-
ery of multiple different siRNA sequences to a given cell can
be ensured. Moreover, it seems that the development of sim-
ple transfection reagents for use in systems biology applica-
tions may now be a realistic possibility. Aptamers could be
pre-appended to streptavidin, and these conjugates in turn
mixed with any set or library of biotinylated siRNAs in
order to make a one-step, ready-to-use transfection reagent.
The simplicity of such a method relative to current proced-
ures (such as frequently irreproducible transfections with
lipid reagents or series of complex packaging steps with
viral vectors) would greatly expand the use of large siRNA
sets in many molecular biology applications.
While our current results are limited to LNCaP cells which
naturally express PSMA, the internalization of an anti-PSMA
antibody has previously been observed for a number of other
cell lines that have been engineered to stably or transiently
express PSMA (33,34). Thus it seems likely that the aptamer-
mediated delivery of siRNA may prove useful for any cell
type that normally expresses PSMA or that can be engineered
to express PSMA. Moreover, since aptamers can be selected
to bind a wide variety of cells (10–13,35), we envision that
additional, cell-speciﬁc transfection reagents will be
developed and that the method described here for prostate
tumor cells may become a general strategy for the speciﬁc
delivery of siRNA to almost any cell type.
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